Unfortunately, because of the dose-limiting toxicities attributed to inhibition of the wild-type (WT) EGFR, these second-generation irreversible inhibitors (Fig. 1) including 3 (afatinib)13, 4 (neratinib)14, 5 (dacomitinib)15 did not improve clinical efficacy for NSCLC patients who have developed T790M acquired resistance. This evidence concerns the gene EGFR and non-small cell lung carcinoma.